Kneu Health, a precision neurology platform for Parkinson’s and dementia, has closed a £4.2 million oversubscribed seed round.

Co-led by Oxford Science Enterprises and Cedars-Sinai, with participation from Social Impact Enterprises, JIMCO, G.K. Goh Ventures and SXSW London, the funding will accelerate US expansion by scaling Parkinson’s deployments, expanding commercial capacity, and publishing outcomes data, while also advancing dementia monitoring.

The round brings Kneu’s total funding to date to $11.2m.